This bill reauthorizes the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs and makes layered changes to funding, commercialization, outreach, procurement, and oversight. It phases up agency set‑aside rates for SBIR/STTR over several fiscal years, extends multiple pilot programs and reporting requirements, and creates new program authorities for fellowships, technical and business assistance, and I–Corps participation.
Practically, the Act aims to convert more R&D awards into sellable products and government contracts: it mandates training for acquisition staff on Phase III opportunities, creates a Technology Commercialization Official in each participating agency, requires richer public reporting (including subcontracted research institutions and minority‑serving classifications), and adds commercialization impact metrics. It also narrows eligibility where foreign control risks are identified—affecting some VC/PE‑owned firms—and establishes new oversight and GAO reporting requirements that will change both agency and awardee compliance workloads.
At a Glance
What It Does
Reauthorizes SBIR/STTR and raises agency set‑aside percentages through 2032; creates fellowship and internship authorities tied to Phase II awardees; expands allowable technical and business assistance (including specific dollar caps per Phase); requires procurement training and Phase III simplification; tightens eligibility around foreign ownership of VC/PE‑backed firms.
Who It Affects
Federal agencies that operate SBIR/STTR (e.g., DOD, NIH, NASA, DOE, NSF), small high‑technology firms and their research subcontractors (including minority‑serving institutions), procurement officers and procurement center representatives, venture capital/private equity ownership structures, and the SBA which must expand reporting and program administration.
Why It Matters
The bill shifts emphasis from R&D awards alone to commercialization and government transition, increases predictable program funding over time, and raises transparency about research partners—measures that will alter awardee behavior, contracting practice, and investor structuring.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill extends SBIR and STTR authorities and adjusts the programs’ budgetary foothold inside federal agencies: set‑aside percentages for SBIR rise in scheduled steps to 7 percent by FY2032, and STTR shares climb to 1 percent by FY2032. That changes the baseline level of agency spending reserved for small business R&D and is a long‑term funding signal to both agencies and applicants.
To push awardees toward commercialization, the Act layers new tools on top of existing Phase I/II awards. Agencies get explicit fellowship and internship authorities to place students and postdocs with successful Phase II firms (with outreach obligations to women and disadvantaged groups and a 3 percent funding cap for agencies not using another specified authority).
It codifies technical and business assistance with clear per‑project caps ($6,500 for Phase I; $50,000 for Phase II), allows that money to pay staff or training, and requires participating agencies to offer or allow I–Corps (or equivalent) participation to teams.On the government side, the bill requires procurement workforce training on Phase III acquisitions, expands the role of procurement center representatives to advocate Phase III transitions, and directs agencies to develop standardized solicitation language and model contract clauses for Phase I–III. It also creates a Technology Commercialization Official at each agency charged with coordinating commercialization paths, tracking commercialization results, and reporting to SBA.
The bill increases public transparency by requiring the SBIR/STTR database to list subcontracted research institutions and identify minority‑serving classifications and accelerates multiple pilot authorities and reporting obligations.Finally, the Act adds targeted guardrails and measurement: it codifies limits that can bar SBIR awards to small businesses majority‑owned by VC/PE if those firms are linked to covered foreign entities, and it orders a commercialization impact assessment for high‑volume Phase II recipients plus a GAO report on diversity and commercialization. These provisions create new compliance and verification duties for awardees and agencies and add new metrics intended to show whether SBIR/STTR investments produced non‑SBIR revenue or contracts.
The Five Things You Need to Know
SBIR set‑aside rates increase in stages to 7% of agency extramural R&D budgets by fiscal year 2032 (4% in FY2026–27; 5% in FY2028–29; 6% in FY2030–31; 7% FY2032+).
STTR set‑aside percentages rise to 1% by fiscal year 2032 via stepped increases (0.5% FY2026–27; 0.65% FY2028–29; 0.8% FY2030–31; 1% FY2032+).
The bill authorizes fellowship/internship awards tied to Phase II recipients, limits non‑mm authority agencies to using up to 3% of required SBIR/STTR expenditures for those fellowships, and mandates enhanced outreach to women and disadvantaged participants.
Technical/business assistance funding is standardized: agencies must permit recipients to use up to $6,500 on Phase I projects and up to $50,000 on Phase II projects for vendor services, staff, or training; agencies must also offer I–Corps (or equivalent) options and permit award funds to pay participation costs.
The Act bars SBIR eligibility for small businesses majority‑owned by multiple VC/PE firms if the concern is owned or controlled by a ‘covered foreign entity’; the bill also requires a Technology Commercialization Official at each agency and expanded procurement training and Phase III reporting.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Reauthorize SBIR/STTR and extend FAST program
Sec. 101 removes the existing sunset language and extends the SBIR/STTR statutory authorities; Sec. 102 extends the FAST (Federal and State Technology partnership) program through September 30, 2030. For agencies and awardees this simply preserves the programs and some associated state partnership authorities for the next multi‑year period.
Boost set‑asides, fellowships, outreach, and assistance rules
This cluster contains the stepped schedule raising SBIR and STTR set‑aside percentages through 2032 and adds programmatic authorities: fellowship grants for Phase II awardees to host students/postdocs, explicit outreach to minority‑serving and low‑participation States, and a rehaul of technical/business assistance permitting recipients to select vendors or use award funds for hiring and training. Practical implication: agencies must adjust budgeting, outreach plans, and award language; applicants gain clearer, capped funding for commercialization support.
Commercialization push: procurement training, Tech Commercialization Official, Phase III fixes
The bill forces acquisition workforce training on Phase III mechanics (data rights, sole‑source awards), creates an agency Technology Commercialization Official responsible for shepherding SBIR/STTR tech into Phase III and non‑SBIR contracts, and requires reporting when DOD denies Phase III. Agencies will need to resource internal commercialization roles and update acquisition guidance; success depends on agency willingness to prioritize Phase III transitions in procurement pipelines.
Extend and expand pilots and processing assistance
This Title extends a variety of pilots (Direct to Phase II, commercialization readiness, Phase 0, commercialization assistance pilots, due diligence programs to assess security risks) to 2030 and slightly raises the administrative transfer rate to SBA for program administration (e.g., transfers of a portion of funds to SBA). It also clarifies that a portion of agency funds can be used for outreach to low‑participation States. In short, the bill preserves experimental authorities and shifts some admin costs and responsibilities.
Reporting, oversight, GAO/GAO‑type studies and commercialization metrics
Requires expanded annual reporting to Congressional small‑business committees and public posting, a Comptroller General study on diversification and commercialization, extension of award timeliness reporting, and creation of a commercialization impact assessment for high‑volume Phase II recipients. The practical effect is stronger transparency and new performance metrics—agencies will collect more data and face external evaluation of whether SBIR/STTR produces measurable non‑SBIR revenue and contract wins.
Technical cleanups, SBIC inclusion, and Phase III/sole‑source language
Adds SBICs (small business investment companies) explicitly in statutory references, refines language around private equity/VC ownership and ownership limits, and clarifies headings and Phase III sole‑source justification language. These are drafting fixes but include a meaningful policy change: SBA must create size standards for firms participating under the new ownership rules.
This bill is one of many.
Codify tracks hundreds of bills on Technology across all five countries.
Explore Technology in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Small advanced‑technology firms that win Phase II awards — gain clearer, capped funds for commercialization and training (Phase I: $6,500 cap; Phase II: $50,000 cap) and expanded access to I–Corps and fellowship pipelines that can accelerate talent and market validation.
- Minority‑serving institutions, Tribal colleges, HSIs and other research partners — the bill requires public reporting of subcontracted research institutions and mandates enhanced outreach and inclusion in fellowship and STTR/SBIR outreach, increasing visibility and potential subcontract opportunities.
- Federal procurement and transition personnel — contracting officers and procurement center representatives receive mandated training on Phase III acquisitions and new directives to advocate transitions, which should reduce ambiguity on sole‑source and data‑rights issues when agencies want to buy SBIR‑developed tech.
- SBA and its SBIR program office — receives new reporting authority and a transfer mechanism that increases its administrative resources (10% transfers from certain agency funds) to run outreach, data collection, and oversight functions.
- Investors and SBICs — SBICs are expressly referenced in statute, and commercialization focus and Phase III standardization may create clearer exit and contract pathways for investors backing small tech firms.
Who Bears the Cost
- Federal agencies with SBIR/STTR programs — must allocate higher percentages of R&D budgets to SBIR/STTR (reducing flexibility for other programs), absorb reporting and database upgrades, institute procurement training, and in some cases transfer funds to SBA for program administration.
- Small businesses majority‑owned by multiple VC/PE firms with foreign links — face new eligibility scrutiny or disqualification if tied to a covered foreign entity, potentially forcing restructurings or blocking certain firms from SBIR awards.
- Contracting shops and prime contractors — must adapt to standardized Phase III solicitation language, additional advocacy responsibilities, and potentially faster timelines for Phase III transitions, requiring process changes and time investment.
- SBA — while receiving transfers, SBA will also carry heavier administrative obligations (data collection, commercialization impact assessments, reporting) that may require staffing and systems work to implement effectively.
- Research institutions and subcontractors — increased public reporting of subcontract relationships and minority‑serving designations may require data collection and greater disclosure of partner arrangements, raising administrative overhead and IP/confidentiality screening needs.
Key Issues
The Core Tension
The central dilemma is promoting rapid commercialization and safeguarding national security without unduly constraining agency flexibility or chilling investment: the bill seeks to convert R&D into deployable goods and ensure secure ownership, but doing so requires trade‑offs in agency budget allocations, heavier compliance and reporting burdens, and new ownership screening that could push investors and firms into complex, potentially counterproductive workarounds.
The Act amplifies commercialization incentives and transparency, but it also imports implementation complexity. Raising set‑aside percentages steadily shifts agency budgeting priorities; agencies will need to reconcile those commitments with mission R&D, potentially rebalancing intramural and extramural portfolios.
The fellowship and outreach authorities are limited by funding caps (3% for agencies not using other authorities), so the practical impact depends on how agencies combine those caps with other program funds. The technical/business assistance caps ($6,500 Phase I; $50,000 Phase II) create useful predictability but could be insufficient for some commercialization pathways, creating pressure to redesign other award terms.
The ownership restrictions targeting VC/PE‑owned firms tied to covered foreign entities introduce a hard national‑security overlay but raise definitional and enforcement questions: VC/PE structures often involve layered entities, limited partners, and complex governance that complicate an ownership/control determination. Firms may restructure or shift ownership to retain eligibility; conversely, stricter screens could deter certain investment.
The commercialization impact assessment targets firms with 50+ Phase II awards — an intentionally narrow cohort — which risks selection bias and may not capture commercialization pathways common to newer or smaller firms. Finally, expanded data collection (subcontractor identities and classifications) increases transparency but raises confidentiality and IP concerns that agencies must manage carefully.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.